Leading Expert in Women’s Health Elected to Guided Therapeutics Board of Directors

Guided Therapeutics, Inc. (Pink Sheets: GTHP) today announced that Jonathan M. Niloff, M.D., a leading expert in Gynecology, quality improvement and healthcare cost containment, was elected to the company’s board of directors, at the annual meeting of stockholders.

Dr. Niloff, 56, joins Mark L. Faupel, Ph.D., William E. Zachary, Jr., John E. Imhoff, M.D., Ronald W. Hart, Ph. D., Michael C. James and Ronald W. Allen on the board.

"We are pleased with the addition of Dr. Niloff to the board of directors and re-election of our standing board by our stockholders,” said Mark L. Faupel, Ph.D., chief executive officer and president of Guided Therapeutics. "Dr. Niloff has specific experience in evaluating new medical technology and its implications for cost containment and reimbursement. We believe his many professional contacts in the Ob-Gyn community can aid in the development and marketing of our cervical cancer detection technology.”

Dr. Niloff currently serves as Chief Medical Officer of MedVentive and is an Associate Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School. Prior to joining MedVentive, Dr. Niloff served as President of the Beth Israel Deaconess Physicians Organization, Medical Director for Obstetrics and Gynecology for its Affiliated Physicians Group, and Chief of Gynecology at New England Deaconess Hospital. He has extensive expertise in all aspects of medical cost and quality improvement and has published extensively on the topic of gynecologic oncology, including the development of the CA125 test for ovarian cancer. Dr. Niloff received his undergraduate education at The Johns Hopkins University, an M.D. degree from McGill University and an MBA degree from Boston University.

About Guided Therapeutics

Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless test for the early detection of disease that leads to cervical cancer. The technology is designed to provide an objective result at the point of care thereby improving the management of cervical disease. Unlike Pap and HPV tests, the device does not require a painful tissue sample and results are known immediately. GT has also entered into a partnership with Konica Minolta Opto to develop a non-invasive test for Barrett’s Esophagus using the LightTouch™ technology platform. For more information, visit GT’s web site www.guidedinc.com.

The Guided Therapeutics LightTouch™ Cervical Scanner is an investigational device and is limited by federal law to investigational use.

"Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics’ actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include: the early stage of products in development, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the uncertainty of capital to develop products, the uncertainty of regulatory approval of products, dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors” in Guided Therapeutics’ reports filed with the SEC, including Guided Therapeutics’ Annual Report on Form 10-KA for the fiscal year ended December 31, 2009 and subsequent quarterly reports.